SOST and osteoporosis: Monoclonal antibodies against sclerostin (romosozumab [218,219]) have proven in clinical trials to be a very efficient osteo-anabolic approach to the treatment of osteoporosis, since they increase bone formation, bone mass, and bone strength [220], therefore decreasing markedly fracture risk in treated patients.